Mike Hollan

Pacira BioSciences’ CEO discusses research into pain treatment that has less chance of creating dependency and addiction issues.

Alongside regulations from the IRA, oncology R&D is set to face unique challenges when MFN is enforced.

Peter Rubin discusses how the industry is an ecosystem and each of the parts will feel the impact differently.

Ryan Quigley, CEO of Inizio, explains how AI, personalized medicine, and GLP 1s are shaping commercialization trends.

Ryan Quigley, CEO of Inizio, discusses how advancement in science are changing the pace of commercialization.

The HOSP Alliance leader discusses the role of specialty pharmacies in the current market.

The company announced the plans as President visited the UK.

Ryan Quigley, CEO of Inizio, discusses how his experience as Chief Operating Officer shaped his journey to CEO.

The new members include individuals who have ties to fringe medical communities.

Updates to its policies have made FDA’s CRLs a key talking point.

The new administration has a different perspective of vaccines than the previous administration, causing confusion with the public.

Key points from our recent webinar on the President’s MFN order.

The company plans to switch to a partner-model for international markets.

The President issued a memo directing HHS and FDA to enforce strict regulations against potentially misleading advertising.

The agency noted ongoing safety violations at the location.

Executives are exploring various strategies to prepare for an uncertain pricing environment in the coming months and years.

The company says addressing the issues raised in the CRL could take years.

The list prevents the import of ingredients from potentially dangerous facilities.

WHO designates GLP-1 medications for diabetes as essential, aiming to improve access and affordability for patients worldwide.

Marc Stapley, CEO of Veracyte, reviews upcoming developments in the diagnostic space.

These drugs have quickly become household names due to their popularity as weight loss medications.

The two companies issued statements detailing the number of studies about the vaccines’ impact.

As more companies announce layoffs and other restructuring plans, industry experts are asking what will happen next.

The OSE Immunotherapeutics CEO discusses recent develops with this potentially game-changing space in oncology.

Marc Stapley, CEO of Veracyte, explains how investors are reacting to recent advancements in cancer care.

Noah Nasser discusses how data silos cause complications with researchers.

The company pointed the President to existing published research and pledged to post more to its site.

Marc Stapley, CEO of Veracyte, discusses the importance of ongoing evidence collection.

As the GLP market begins to settle, pharma companies and investors are looking to predict what comes next.

The feature will be available on the company’s platform Nuro.